Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Cossburn

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Practical Neurology|September 17, 2011
The Neurological Grand Round: room for updating?Mark Cossburn
Lancet (London, England)|March 9, 2017
Immunoablation and aHSCT for aggressive multiple sclerosisMatthew Harris, Mark Cossburn, Ralph Gregory
BMJ Case Reports|May 3, 2023
Anti-Yo paraneoplastic cerebellar degeneration in a patient with stage IV ovarian adenocarcinoma during bevacizumab maintenance therapyAlice Giucca, Hamish Morrison, Thomas Wilson, et al.
Rheumatology (Oxford, England)|August 3, 2021
An important diagnostic clue for neuro-Behçet's disease: the 'cascade sign'Jonathan Cleaver, Hamish Morrison, Shelley A Renowden, et al.
Neuroscience Letters|June 27, 2012
Genotype-phenotype correlation for non-HLA disease associated risk alleles in multiple sclerosisKatharine Harding, Gillian Ingram, Mark Cossburn, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|December 26, 2013
Predicting autoimmunity after alemtuzumab treatment of multiple sclerosisLaura Azzopardi, Sara A J Thompson, Katherine E Harding, et al.
Nature|August 12, 2011
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis, , Stephen Sawcer, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Practical Neurology|September 17, 2011
The Neurological Grand Round: room for updating?Mark Cossburn
Lancet (London, England)|March 9, 2017
Immunoablation and aHSCT for aggressive multiple sclerosisMatthew Harris, Mark Cossburn, Ralph Gregory
BMJ Case Reports|May 3, 2023
Anti-Yo paraneoplastic cerebellar degeneration in a patient with stage IV ovarian adenocarcinoma during bevacizumab maintenance therapyAlice Giucca, Hamish Morrison, Thomas Wilson, et al.
Rheumatology (Oxford, England)|August 3, 2021
An important diagnostic clue for neuro-Behçet's disease: the 'cascade sign'Jonathan Cleaver, Hamish Morrison, Shelley A Renowden, et al.
Neuroscience Letters|June 27, 2012
Genotype-phenotype correlation for non-HLA disease associated risk alleles in multiple sclerosisKatharine Harding, Gillian Ingram, Mark Cossburn, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|December 26, 2013
Predicting autoimmunity after alemtuzumab treatment of multiple sclerosisLaura Azzopardi, Sara A J Thompson, Katherine E Harding, et al.
Nature|August 12, 2011
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis, , Stephen Sawcer, et al.
Pageof 1